Clinical trial / 2018
Resveratrol (500 mg/day) as an adjuvant to meloxicam safely improved pain and physical function in patients with knee osteoarthritis over 90 days.
A 90-day double-blind, placebo-controlled trial in 110 patients with knee osteoarthritis evaluated the effect of adding 500 mg/day of resveratrol to meloxicam. Resveratrol significantly improved pain, functional activity, and associated symptoms compared with placebo. Clinical and biochemical markers of liver and kidney function, lipid profile, and hematology showed that the combination was safe and well tolerated.
- Study type
- Double-blind, placebo-controlled, randomized multicenter trial
- Who was studied
- 110 patients with knee osteoarthritis
- What was measured
- Pain severity and functional disability (WOMAC), lipid profile, hematological markers, liver and kidney functions, vitamin D level
THE PAPER
Efficacy and safety of co-administration of resveratrol with meloxicam in patients with knee osteoarthritis: a pilot interventional study.
Hussain SA, Marouf BH, Ali ZS, Ahmmad RS. Clin Interv Aging, 2018.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.